The success of antibody therapeutics is strongly influenced by their multifunctional nature
that couples antigen recognition mediated by their variable regions with effector functions …

Prolactin (PRL) is a peptide hormone mainly secreted from the anterior pituitary gland. PRL
is reported to play a role in pregnancy, mammary gland development, immune modulation …

Background Prolactin receptor (PRLR) is highly expressed in a subset of human breast
cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical …

Antibody drug conjugate (ADC) therapy has become one of the most promising approaches
in cancer immunotherapy. Bispecific targeting could enhance the efficacy and safety of ADC …

Epidermal growth factor receptor variant III (EGFRvIII) is highly and specifically expressed in
a subset of lethal glioblastoma (GBM), making the receptor a unique therapeutic target for …

Background Though tamoxifen achieves success in treating estrogen receptor α (ERα)-
positive breast cancer, the followed development of tamoxifen resistance is a common …

Bispecific antibodies comprise extremely diverse architectures enabling complex modes of
action, such as effector cell recruitment or conditional target modulation via dual targeting …

Background: Colorectal cancer is a commonly diagnosed cancer with high mortality
worldwide. Postoperative recidivation and metastasis still are the main challenges in clinical …

Rapid and efficient bispecific antibody (BsAb) production for industrial applications is still
facing many challenges. We reported a technology platform for generating bispecific IgG …

A bispecific antibody (bsAb) is a class of engineered antibody molecules that simultaneously
binds to two different antigens by having two kinds of antigen-binding domains. One of the …